Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 5/20 | 0.51 |
| ▸ | FADS1 | O60427 | 1/20 | 0.51 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.50 |
| ▸ | FLT1 | P17948 | 1/20 | 0.47 |
| ▸ | SYK | P43405 | 1/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.47 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.47 |
| ▸ | CLK1 | P49759 | 1/20 | 0.46 |
| ▸ | LCK | P06239 | 1/20 | 0.46 |
| ▸ | RET | P07949 | 2/20 | 0.46 |
| ▸ | KIF5B | P33176 | 2/20 | 0.46 |
| ▸ | KDR | P35968 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.45 |
| ▸ | RAF1 | P04049 | 2/20 | 0.44 |
| ▸ | BRAF | P15056 | 2/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5314379 | 0.91 | EGFR (0.56) | EGFRFADS1PIP4K2CFLT1SYK | |
| Hydrochloric Acid SCHEMBL5472957 | 0.90 | EGFR (0.56) | EGFRFADS1PIP4K2CFLT1SYK | |
| SCHEMBL5369046 | 0.87 | EGFR (0.60) | EGFRFADS1PIP4K2CFLT1SYK | |
| SCHEMBL5316590 | 0.86 | EGFR (0.52) | EGFRFADS1PIP4K2CFLT1SYK | |
| Hydrochloric Acid SCHEMBL5465321 | 0.85 | EGFR (0.51) | EGFRFADS1PIP4K2CFLT1SYK | |
| SCHEMBL5312123 | 0.83 | EGFR (0.49) | EGFRFADS1PIP4K2CFLT1DYRK1A | |
| SCHEMBL5315196 | 0.82 | EGFR (0.67) | EGFRFADS1PIP4K2CFLT1DYRK1A | |
| SCHEMBL5315839 | 0.82 | SYK (0.52) | EGFRFADS1PIP4K2CFLT1SYK | |
| Hydrochloric Acid SCHEMBL5334353 | 0.82 | EGFR (0.48) | EGFRFADS1PIP4K2CFLT1DYRK1A | |
| SCHEMBL5468539 | 0.82 | PIP4K2C (0.64) | EGFRFADS1PIP4K2CFLT1DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007056215-A9 | N-ARYL-THIENOPYRIMIDIN-4-AMINES AND THE USE THEREOF | CYTOVIA INC (US) | 2007-09-13 | — | — | WO | claimed |
| WO-2007056215-A2 | N-ARYL-THIENOPYRIMIDIN-4-AMINES AND THE USE THEREOF | CYTOVIA, INC. (US) | 2007-05-18 | — | — | WO | claimed |
| US-20070099877-A1 | N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2007-05-03 | — | — | US | claimed |
| WO-2007056215-A9 | N-ARYL-THIENOPYRIMIDIN-4-AMINES AND THE USE THEREOF | CYTOVIA INC (US) | 2007-09-13 | — | — | WO | disclosed |
| WO-2007056215-A2 | N-ARYL-THIENOPYRIMIDIN-4-AMINES AND THE USE THEREOF | CYTOVIA, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| US-20070099877-A1 | N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099877-A1 | N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP4, CASP3, API5 | EGFR 1226/4885FADS1 1782/4885PIP4K2C 2195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.